Concerns related to COVID‐19 pandemic among patients with inflammatory bowel disease and its influence on patient management
- 15 April 2020
- journal article
- letter
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 50 (5), e13233
- https://doi.org/10.1111/eci.13233
Abstract
A novel coronavirus, currently identified as COVID‐19, was recently defined as the cause of a cluster of patients with pneumonia of unknown origin that was initially reported from Wuhan, Hubei province, People’s Republic of China.Keywords
This publication has 11 references indexed in Scilit:
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- The novel Chinese coronavirus (2019‐nCoV) infections: Challenges for fighting the stormEuropean Journal of Clinical Investigation, 2020
- ECCO Guidelines on Therapeutics in Crohn's Disease: Medical TreatmentJournal of Crohn's and Colitis, 2020
- High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel diseaseScandinavian Journal of Gastroenterology, 2019
- European Crohn’s and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel DiseaseJournal of Crohn's and Colitis, 2019
- Reproducibility and Transportability of the Absence of Incremental Infectious Adverse Events in Patients With Higher Anti-TNF Drug LevelsInflammatory Bowel Diseases, 2018
- Reduction in TIMP‐2 serum levels predicts remission of inflammatory bowel diseasesEuropean Journal of Clinical Investigation, 2018
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current ManagementJournal of Crohn's and Colitis, 2017
- Production of interleukin-1b and tumor necrosis factor--a by peripheral blood human mononuclear cells in active and inactive stages of ulcerative colitis.1995